Developing Novel Precision Oncology Therapeutics

We are a clinical-stage global biopharmaceutical company developing a pipeline of novel precision therapies for people with cancer.

Clinical Stage Assets

ROS1-positive non-small cell lung cancer

Phase 2

IDH1-mutant Grades 2 and 3 glioma, cholangiocarcinoma and other tumors

Phase 2

April 10, 2024

March 25, 2024

March 4, 2024